Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

por Gregorc, V, Santoro, A, Bennicelli, E, Punt, C J A, Citterio, G, Timmer-Bonte, J N H, Caligaris Cappio, F, Lambiase, A, Bordignon, C, van Herpen, C M L
Publicado 2009

The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models

por Faur, N, Araud, L, Laroche-Clary, A, Kanno, J, Toutain, J, Yamori, T, Robert, J, Le Morvan, V
Publicado 2009

Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion

por Meng, X N, Jin, Y, Yu, Y, Bai, J, Liu, G Y, Zhu, J, Zhao, Y Z, Wang, Z, Chen, F, Lee, K-Y, Fu, S B
Publicado 2009

Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer

por Ryan, A J, Napoletano, S, Fitzpatrick, P A, Currid, C A, O'Sullivan, N C, Harmey, J H
Publicado 2009

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness

por Thompson Coon, J S, Liu, Z, Hoyle, M, Rogers, G, Green, C, Moxham, T, Welch, K, Stein, K
Publicado 2009

Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma

por Jacobson, B A, De, A, Kratzke, M G, Patel, M R, Jay-Dixon, J, Whitson, B A, Sadiq, A A, Bitterman, P B, Polunovsky, V A, Kratzke, R A
Publicado 2009

Androgen-related expression of G-proteins in ovarian cancer

por Sheach, L A, Adeney, E M, Kucukmetin, A, Wilkinson, S J, Fisher, A D, Elattar, A, Robson, C N, Edmondson, R J
Publicado 2009

The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage

por Howell, S J, Searle, C, Goode, V, Gardener, T, Linton, K, Cowan, R A, Harris, M A, Hopwood, P, Swindell, R, Norman, A, Kennedy, J, Howell, A, Wardley, A M, Radford, J A
Publicado 2009

Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer

por Daskalaki, A, Agelaki, S, Perraki, M, Apostolaki, S, Xenidis, N, Stathopoulos, E, Kontopodis, E, Hatzidaki, D, Mavroudis, D, Georgoulias, V
Publicado 2009

Identification of retinoic acid-regulated nuclear matrix-associated protein as a novel regulator of gastric cancer

por Li, J, Ng, E K O, Ng, Y P, Wong, C Y P, Yu, J, Jin, H, Cheng, V Y Y, Go, M Y Y, Cheung, P K F, Ebert, M P A, Tong, J, To, K F, Chan, F K L, Sung, J J Y, Ip, N Y, Leung, W K
Publicado 2009

Analogues of Y27632 increase gap junction communication and suppress the formation of transformed NIH3T3 colonies

por Hampson, L, He, X T, Oliver, A W, Hadfield, J A, Kemp, T, Butler, J, McGown, A, Kitchener, H C, Hampson, I N
Publicado 2009

FGF8 isoform b expression in human prostate cancer

por Gnanapragasam, V J, Robinson, M C, Marsh, C, Robson, C N, Hamdy, F C, Leung, H Y
Publicado 2003

Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1–5

por Hsieh, J-L, Wu, C-L, Lai, M-D, Lee, C-H, Tsai, C-S, Shiau, A-L
Publicado 2003

Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate

por Amat, S, Bougnoux, P, Penault-Llorca, F, Fétissof, F, Curé, H, Kwiatkowski, F, Achard, J-L, Body, G, Dauplat, J, Chollet, P
Publicado 2003

Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer

por Langelotz, C, Schmid, P, Jakob, C, Heider, U, Wernecke, K D, Possinger, K, Sezer, O
Publicado 2003

A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer

por Smith, R E, Tchekmedyian, N S, Chan, D, Meza, L A, Northfelt, D W, Patel, R, Austin, M, Colowick, A B, Rossi, G, Glaspy, J
Publicado 2003

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer

por Saini, A, Norman, A R, Cunningham, D, Chau, I, Hill, M, Tait, D, Hickish, T, Iveson, T, Lofts, F, Jodrell, D, Ross, P J, Oates, J
Publicado 2003

Cost of a 5-year lung cancer survivor: symptomatic tumour identification vs proactive computed tomography screening

por Castleberry, A W, Smith, D, Anderson, C, Rotter, A J, Grannis, F W
Publicado 2009

CD26 expression on T cell lines increases SDF-1-α-mediated invasion

por Havre, P A, Abe, M, Urasaki, Y, Ohnuma, K, Morimoto, C, Dang, N H
Publicado 2009

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer

por Chua, W, Goldstein, D, Lee, C K, Dhillon, H, Michael, M, Mitchell, P, Clarke, S J, Iacopetta, B
Publicado 2009